|
[1]
|
Quezada, S.A. and Peggs, K.S. (2013) Exploiting CTLA-4, PD-1 and PD-L1 to Reactivate the Host Immune Response against Cancer. British Journal of Cancer, 108, 1560-1565. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Schütz, F., Stefanovic, S., Mayer, L., et al. (2017) PD-1/PD-L1 Pathway in Breast Cancer. Oncology Research and Treatment, 40, 294-297. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Wu, X., Gu, Z., Chen, Y., et al. (2019) Application of PD-1 Blockade in Cancer Immunotherapy. Computational and Structural Biotechnology Journal, 17, 661-674. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Juneja, V.R., Mcguire, K.A., Manguso, R.T., et al. (2017) PD-L1 on Tumor Cells Is Sufficient for Immune Evasion in Immunogenic Tumors and Inhibits CD8 T Cell Cytotoxicity. The Journal of Experimental Medicine, 214, 895-904. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Ohaegbulam, K.C., Assal, A., Lazar-Molnar, E., et al. (2015) Human Cancer Immunotherapy with Antibodies to the PD-1 and PD-L1 Pathway. Trends in Molecular Medicine, 21, 24-33. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Kwiecien, I., Skirecki, T., Polubiec-Kownacka, M., et al. (2019) Immunophenotype of T Cells Expressing Programmed Death-1 and Cytotoxic T Cell Antigen-4 in Early Lung Cancer: Local vs. Systemic Immune Response. Cancers (Basel), 11, 567. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Sharpe, A.H., Wherry, E.J., Ahmed, R., et al. (2007) The Function of Programmed Cell Death 1 and Its Ligands in Regulating Autoimmunity and Infection. Nature Immunology, 8, 239-245. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Keir, M.E., Butte, M.J., Freeman, G.J., et al. (2008) PD-1 and Its Ligands in Tolerance and Immunity. Annual Review of Immunology, 26, 677-704. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Jurado, J.O., Alvarez, I.B., Pasquinelli, V., et al. (2008) Programmed Death (PD)-1: PD-Ligand 1/PD-Ligand 2 Pathway Inhibits T Cell Effector Functions during Human Tuberculosis. Journal of Immunology (Baltimore, Md: 1950), 181, 116-125. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Alvarez, I.B., Pasquinelli, V., Jurado, J.O., et al. (2010) Role Played by the Programmed Death-1-Programmed Death Ligand Pathway during Innate Immunity against Mycobacterium tuberculosis. The Journal of Infectious Diseases, 202, 524-532. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Peng, W., Liu, C., Xu, C., et al. (2012) PD-1 Blockade Enhances T-Cell Migration to Tumors by Elevating IFN-γ Inducible Chemokines. Cancer Research, 72, 5209-5218. [Google Scholar] [CrossRef]
|
|
[12]
|
He, J., Hu, Y., Hu, M., et al. (2015) Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer. Scientific Reports, 5, Article No. 13110. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Zinselmeyer, B.H., Heydari, S., Sacristán, C., et al. (2013) PD-1 Promotes Immune Exhaustion by Inducing Antiviral T Cell Motility Paralysis. The Journal of Experimental Medicine, 210, 757-774. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Yao, H., Wang, H., Li, C., et al. (2018) Cancer Cell-Intrinsic PD-1 and Implications in Combinatorial Immunotherapy. Frontiers in Immunology, 9, Article No. 1774. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Ghoneum, A., Afify, H., Salih, Z., et al. (2018) Role of Tumor Microenvironment in the Pathobiology of Ovarian Cancer: Insights and Therapeutic Opportunities. Cancer Medicine, 7, 5047-5056. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
(2020) Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019. The Lancet (London, England), 396, 1204-1222.
|
|
[17]
|
Torres, A., Cilloniz, C., Niederman, M.S., et al. (2021) Pneumonia. Nature Reviews Disease Primers, 7, 25. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Cavallazzi, R., Furmanek, S., Arnold, F.W., et al. (2020) The Burden of Community-Acquired Pneumonia Requiring Admission to ICU in the United States. Chest, 158, 1008-1016. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Bein, T., Weber-Carstens, S. and Apfelbacher, C. (2018) Long-Term Outcome after the Acute Respiratory Distress Syndrome: Different from General Critical Illness? Current Opinion in Critical Care, 24, 35-40. [Google Scholar] [CrossRef]
|
|
[20]
|
Sangla, F., Legouis, D., Marti, P.E., et al. (2020) One Year after ICU Admission for Severe Community-Acquired Pneumonia of Bacterial, Viral or Unidentified Etiology. What Are the Outcomes? PLOS ONE, 15, e0243762. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Laporte, L., Hermetet, C., Jouan, Y., et al. (2018) Ten-Year Trends in Intensive Care Admissions for Respiratory Infections in the Elderly. Annals of Intensive Care, 8, 84. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
World Health Organization (2021) Global Tuberculosis Report 2021. World Health Organization, Geneva.
|
|
[23]
|
Walzl, G., Mcnerney, R., Du Plessis, N., et al. (2018) Tuberculosis: Advances and Challenges in Development of New Diagnostics and Biomarkers. The Lancet Infectious Diseases, 18, e199-e210. [Google Scholar] [CrossRef]
|
|
[24]
|
World Health Organization (2018) Global Tuberculosis Re-port 2018. World Health Organization, Geneva.
|
|
[25]
|
World Health Organization (2019) Global Tuberculosis Report 2019. World Health Organization, Geneva.
|
|
[26]
|
World Health Organization (2020) Global Tuberculosis Report 2020. World Health Organization, Geneva.
|
|
[27]
|
Zwerling, A., Van Den Hof, S., Scholten, J., et al. (2012) Interferon-Gamma Release Assays for Tuberculosis Screening of Healthcare Workers: A Systematic Review. Thorax, 67, 62-70. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Liang, H.Y., Li, X.L., Yu, X.S., et al. (2009) Facts and Fiction of the Relationship between Preexisting Tuberculosis and Lung Cancer Risk: A Systematic Review. International Journal of Cancer, 125, 2936-2944. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Yu, Y.H., Liao, C.C., Hsu, W.H., et al. (2011) Increased Lung Cancer Risk among Patients with Pulmonary Tuberculosis: A Population Cohort Study. Journal of Thoracic Oncology: Official Pub-lication of the International Association for the Study of Lung Cancer, 6, 32-37. [Google Scholar] [CrossRef]
|
|
[30]
|
Brenner, D.R., Boffetta, P., Duell, E.J., et al. (2012) Previous Lung Diseases and Lung Cancer Risk: A Pooled Analysis from the International Lung Cancer Consortium. American Journal of Epidemiology, 176, 573-585. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Leung, C.C., Hui, L., Lee, R.S., et al. (2013) Tuberculosis Is Associated with Increased Lung Cancer Mortality. The International Journal of Tuberculosis and Lung Disease: The Official Jour-nal of the International Union against Tuberculosis and Lung Disease, 17, 687-692. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Getahun, H., Matteelli, A., Chaisson, R.E., et al. (2015) Latent Mycobac-terium tuberculosis Infection. The New England Journal of Medicine, 372, 2127-2135. [Google Scholar] [CrossRef]
|
|
[33]
|
Rangaka, M.X., Cavalcante, S.C., Marais, B.J., et al. (2015) Con-trolling the Seedbeds of Tuberculosis: Diagnosis and Treatment of Tuberculosis Infection. The Lancet (London, England), 386, 2344-2353. [Google Scholar] [CrossRef]
|
|
[34]
|
韩鹏勇, 塔娜, 等. 人CD8~+T细胞基因调控网络研究[J]. 西北农业学报, 2019, 28(6): 861-867.
|
|
[35]
|
吴荷宁, 彭民. CD4~+T、CD8~+T淋巴细胞在新型冠状病毒肺炎中的研究进展[J]. 天津医科大学学报, 2021, 27(6): 658-660+664.
|
|
[36]
|
安健, 孙蓬明. T淋巴细胞亚群检测在子宫内膜癌中的应用价值[J], 中国妇产科临床杂志, 2020, 21(4): 428-431.
|
|
[37]
|
Westmeier, J., Paniskaki, K., Karaköse, Z., et al. (2020) Impaired Cytotoxic CD8(+) T Cell Response in Elderly COVID-19 Patients. mBio, 11, e02243-20. [Google Scholar] [CrossRef]
|
|
[38]
|
Horkova, V., Drobek, A., Mueller, D., et al. (2020) Dynamics of the Coreceptor-LCK Interactions during T Cell Development Shape the Self-Reactivity of Peripheral CD4 and CD8 T Cells. Cell Reports, 30, 1504-1514.e7. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Bardhan, K., Anagnostou, T. and Boussiotis, V.A. (2016) The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation. Frontiers in Immunology, 7, 550. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Trefny, M.P., Kaiser, M., Stanczak, M.A., et al. (2020) PD-1(+) Natural Killer Cells in Human Non-Small Cell Lung Cancer Can Be Activated by PD-1/PD-L1 Blockade. Cancer Im-munology, Immunotherapy: CII, 69, 1505-1517. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
Cooper, W.A., Tran, T., Vilain, R.E., et al. (2015) PD-L1 Ex-pression Is a Favorable Prognostic Factor in Early Stage Non-Small Cell Carcinoma. Lung Cancer (Amsterdam, Nether-lands), 89, 181-188. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Lindestam Arlehamn, C.S., Lewinsohn, D., Sette, A., et al. (2014) Antigens for CD4 and CD8 T Cells in Tuberculosis. Cold Spring Harbor Perspectives in Medicine, 4, a018465. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Kauffman, K.D., Sallin, M.A., Sakai, S., et al. (2018) Defective Positioning in Granulomas but Not Lung-Homing Limits CD4 T-Cell Interactions with Mycobacterium tuberculo-sis-Infected Macrophages in Rhesus Macaques. Mucosal Immunology, 11, 462-473. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
袁洁铭, 李理. 老年人T淋巴细胞PD-1高表达在炎症状态下对其功能的影响[J]. 免疫学杂志, 2017, 33(6): 519-524.
|
|
[45]
|
Efremova, M., Rieder, D., Klepsch, V., et al. (2018) Targeting Immune Checkpoints Potentiates Immunoediting and Changes the Dynamics of Tumor Evolution. Nature Communica-tions, 9, Article No. 32. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Ribas, A. and Wolchok, J.D. (2018) Cancer Immunotherapy Using Checkpoint Blockade. Science (New York, NY), 359, 1350-1355. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Wykes, M.N. and Lewin, S.R. (2018) Immune Checkpoint Blockade in Infectious Diseases. Nature Reviews Immunology, 18, 91-104. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Larbi, A., Franceschi, C., Mazzatti, D., et al. (2008) Aging of the Immune System as a Prognostic Factor for Human Longevity. Physiology (Bethesda, Md), 23, 64-74. [Google Scholar] [CrossRef] [PubMed]
|
|
[49]
|
Chinai, J.M., Janakiram, M., Chen, F., et al. (2015) New Immunotherapies Targeting the PD-1 Pathway. Trends in Pharmacological Sciences, 36, 587-595. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Attanasio, J. and Wherry, E.J. (2016) Costimulatory and Coinhibitory Receptor Pathways in Infectious Disease. Immunity, 44, 1052-1068. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
徐若楠, 孙国鹏, 等. PD-1基因的表达调控分子机制研究进展[J]. 中国免疫学杂志, 2020, 36(20): 2540-2546.
|
|
[52]
|
Zhang, Y., Zhou, Y., Lou, J., et al. (2010) PD-L1 Blockade Improves Survival in Experimental Sepsis by Inhibiting Lymphocyte Apoptosis and Reversing Monocyte Dysfunction. Critical Care (London, England), 14, R220. [Google Scholar] [CrossRef] [PubMed]
|
|
[53]
|
Chang, K., Svabek, C., Vazquez-Guillamet, C., et al. (2014) Targeting the Pro-grammed Cell Death 1: Programmed Cell Death Ligand 1 Pathway Reverses T Cell Exhaustion in Patients with Sepsis. Critical Care (London, England), 18, R3. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Guignant, C., Lepape, A., Huang, X., et al. (2011) Programmed Death-1 Levels Correlate with Increased Mortality, Nosocomial Infection and Immune Dysfunctions in Septic Shock Patients. Critical Care (London, England), 15, R99. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Bermejo-Martin, J.F. andaluz-Ojeda, D., Almansa, R., et al. (2016) Defining Immunological Dysfunction in Sepsis: A Requisite Tool for Precision Medicine. The Journal of Infection, 72, 525-536. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Wherry, E.J. and Kurachi, M. (2015) Molecular and Cellular In-sights into T Cell Exhaustion. Nature Reviews Immunology, 15, 486-499. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Tezera, L.B., Bielecka, M.K., Ogongo, P., et al. (2020) Anti-PD-1 Immuno-therapy Leads to Tuberculosis Reactivation via Dysregulation of TNF-α. eLife, 9, e52668. [Google Scholar] [CrossRef]
|
|
[58]
|
Day, C.L., Abrahams, D.A., Bunjun, R., et al. (2018) PD-1 Expression on Mycobacterium tuberculosis-Specific CD4 T Cells Is Associated with Bacterial Load in Human Tuberculosis. Fron-tiers in Immunology, 9, Article No. 1995. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Hassan, S.S., Akram, M., King, E.C., et al. (2015) PD-1, PD-L1 and PD-L2 Gene Expression on T-Cells and Natural Killer Cells Declines in Conjunction with a Reduction in PD-1 Pro-tein during the Intensive Phase of Tuberculosis Treatment. PLOS ONE, 10, e0137646. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Basile, J.I., Liu, R., Mou, W., et al. (2020) Mycobacte-ria-Specific T Cells Are Generated in the Lung During Mucosal BCG Immunization or Infection with Mycobacterium tuberculosis. Frontiers in Immunology, 11, Article ID: 566319. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Pathakumari, B., Devasundaram, S. and Raja, A. (2018) Altered Expression of Antigen-Specific Memory and Regulatory T-Cell Subsets Differentiate Latent and Active Tuberculosis. Immunology, 153, 325-336. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Singh, A., Mohan, A., Dey, A.B., et al. (2017) Programmed Death-1 (+) T Cells Inhibit Effector T Cells at the Pathological Site of Miliary Tuberculosis. Clinical and Experimental Immunology, 187, 269-283. [Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Singh, A., Dey, A.B., Mohan, A., et al. (2014) Programmed Death-1 Re-ceptor Suppresses γ-IFN Producing NKT Cells in Human Tuberculosis. Tuberculosis (Edinburgh, Scotland), 94, 197-206. [Google Scholar] [CrossRef] [PubMed]
|
|
[64]
|
Shen, L., Shi, H., Gao, Y., et al. (2016) The Characteris-tic Profiles of PD-1 and PD-L1 Expressions and Dynamic Changes during Treatment in Active Tuberculosis. Tuberculo-sis (Edinburgh, Scotland), 101, 146-150. [Google Scholar] [CrossRef] [PubMed]
|
|
[65]
|
Singh, A., Mohan, A., Dey, A.B., et al. (2013) Inhibiting the Pro-grammed Death 1 Pathway Rescues Mycobacterium tuberculosis-Specific Interferon γ-Producing T Cells from Apopto-sis in Patients with Pulmonary Tuberculosis. The Journal of Infectious Diseases, 208, 603-615. [Google Scholar] [CrossRef] [PubMed]
|
|
[66]
|
Yin, W., Tong, Z.H., Cui, A., et al. (2014) PD-1/PD-Ls Pathways be-tween CD4 (+) T Cells and Pleural Mesothelial Cells in Human Tuberculous Pleurisy. Tuberculosis (Edinburgh, Scot-land), 94, 131-139. [Google Scholar] [CrossRef] [PubMed]
|